Compare NTRS & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTRS | WST |
|---|---|---|
| Founded | 1889 | 1923 |
| Country | United States | United States |
| Employees | N/A | 10600 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3B | 20.2B |
| IPO Year | N/A | N/A |
| Metric | NTRS | WST |
|---|---|---|
| Price | $133.35 | $280.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $127.77 | ★ $346.78 |
| AVG Volume (30 Days) | ★ 930.2K | 661.6K |
| Earning Date | 01-22-2026 | 10-23-2025 |
| Dividend Yield | ★ 2.40% | 0.31% |
| EPS Growth | ★ 7.22 | 0.17 |
| EPS | ★ 8.58 | 6.75 |
| Revenue | ★ $7,932,900,000.00 | $3,017,900,000.00 |
| Revenue This Year | N/A | $7.01 |
| Revenue Next Year | $4.02 | $6.20 |
| P/E Ratio | ★ $15.53 | $41.51 |
| Revenue Growth | 0.96 | ★ 4.92 |
| 52 Week Low | $81.62 | $187.43 |
| 52 Week High | $135.48 | $348.90 |
| Indicator | NTRS | WST |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 55.28 |
| Support Level | $129.98 | $269.08 |
| Resistance Level | $133.80 | $285.54 |
| Average True Range (ATR) | 2.72 | 7.15 |
| MACD | 0.60 | 1.29 |
| Stochastic Oscillator | 94.34 | 82.62 |
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2024, Northern Trust had assets under custody or administration of $16.8 trillion and assets under management of $1.6 trillion.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.